10-K: Sera Prognostics Reports 2025 Financials, Advances Pipeline

Sera Prognostics, a women's health company, reported a reduced net loss in 2025, bolstered by a recent capital raise and positive clinical trial results for its PreTRM test, while expanding its executive team and product pipeline.

Summary

• Sera Prognostics reported a net loss of $31.9 million for the year ended December 31, 2025, an improvement from a $32.9 million net loss in 2024.
• Revenue for 2025 was $81 thousand, a slight increase from $77 thousand in 2024.
• Operating expenses decreased slightly to $36.585 million in 2025 from $36.712 million in 2024.
• Research and development expenses decreased by $1.6 million to $13.171 million in 2025, primarily due to winding down PRIME study costs.
• Selling and marketing expenses increased by $0.8 million to $6.548 million in 2025, reflecting strategic hiring in the commercial organization.
• General and administrative expenses increased by $0.6 million to $16.702 million in 2025, mainly due to increased personnel costs.
• Other income, net, increased by $0.8 million to $4.585 million in 2025, driven by higher interest income on marketable securities.
• The company completed a public offering in February 2025, raising approximately $53.6 million in net proceeds.
• Cash, cash equivalents, and available-for-sale securities totaled $95.8 million as of December 31, 2025.
• The accumulated deficit reached $311.7 million as of December 31, 2025.
• The company believes its cash runway is sufficient to fund operations through 2028 based on existing plans.
• Amended and Restated Employment Agreements were executed with all executive officers in March 2026, adjusting severance and equity acceleration terms.
• A new at-the-market (ATM) sales agreement was entered into with William Blair & Company, L.L.C. on March 18, 2026, for up to $40.0 million in Class A common stock sales.

Sentiment

Score: 6

Explanation: StockSavvy.ai views this as a moderately positive update. While the company continues to operate at a loss, the significant clinical trial results for PreTRM and the successful capital raise provide a strong foundation for future growth and commercialization efforts, albeit with ongoing market and reimbursement challenges.

Positives

• Net loss decreased from $32.9 million in 2024 to $31.9 million in 2025, indicating improved financial performance.
• Revenue saw a slight increase from $77 thousand in 2024 to $81 thousand in 2025.
• The PRIME study results, published in January 2026, demonstrated significant clinical benefits for the PreTRM test, including a 20% reduction in NICU admissions, a 20% reduction in neonatal morbidity and mortality, a 56% reduction in babies born before 32 weeks, and a 32% reduction in babies born before 35 weeks.
• The PreTRM test-and-treat strategy showed a Number Needed to Screen (NNS) of 4.2 to save a NICU day and 38.5 to save a NICU admission, which is at least three times more effective than the standard of care for short cervix (NNS of 150).
• An aggregate-data meta-analysis of the PRIME and AVERT PRETERM TRIAL studies showed a 22% decreased risk of prolonged hospital stay and a 22% reduction in neonatal morbidity and mortality.
• The American College of Obstetricians and Gynecologists (ACOG) updated its Clinical Consensus in May 2025, emphasizing risk assessments in prenatal care, aligning with the PreTRM test's utility and potentially creating opportunities for guideline inclusion.
• The commercial collaboration agreement with Elevance Health provides early payment for the PreTRM test and facilitates data generation across diverse patient populations.
• The company possesses a proprietary and scalable proteomics and bioinformatics platform, along with extensive biobanks, for developing new diagnostic tests.
• A robust pipeline of diagnostic tests for other major pregnancy conditions, including Molecular Time-to-Birth, Predictive Analytics (LikeMine webapp), Pregnancy Risk Prediction Panel, Preeclampsia, Fetal Growth Restriction, Stillbirth, and Postpartum Depression, is under development.
• Advancements in testing technology, such as whole-blood collection, ambient shipping, and the automated affinity-capture mass-spectrometry (AC-MS) PreTRM assay (launched in 2024), aim to lower costs, improve patient experience, and increase throughput.
• The company maintains a strong intellectual property portfolio with multiple issued U.S. and foreign patents and pending applications, protecting its core technologies.
• The February 2025 Offering successfully raised approximately $53.6 million in net proceeds, extending the company's cash runway through 2028.
• Strategic hires in 2025, including a Chief Commercial Officer and Chief Medical Officer, strengthen the commercial and clinical leadership teams.

Negatives

• The company has incurred net losses since its inception and anticipates continued losses for the foreseeable future, with an accumulated deficit of $311.7 million as of December 31, 2025.
• Net cash used in operating activities significantly increased to $25.623 million in 2025 from $14.189 million in 2024, indicating a higher cash burn rate.
• Substantially all current revenue is derived from the PreTRM test, leading to customer concentration risk, particularly with Elevance Health.
• The company has limited experience in sales and marketing as a standalone entity, which could hinder commercialization efforts.
• Uncertainty remains regarding obtaining and maintaining adequate reimbursement from third-party payers, with many currently having negative coverage determinations or not reimbursing for low-risk preterm birth screening tests.
• State Medicaid programs currently do not reimburse for the company's tests.
• Third-party payers are increasingly requiring prior authorization for testing, which can reduce and/or delay reimbursement amounts.
• The life science industry is characterized by intense competition, with many competitors possessing significantly greater financial resources and expertise.
• Reliance on a limited number of suppliers for critical laboratory instruments and materials poses supply chain risks.
• Inflation, global supply chain disruptions, and evolving trade policies (e.g., tariffs) could increase costs and impact business operations.
• The company's ability to utilize its net operating loss carryforwards may be limited by Section 382 of the Internal Revenue Code.
• Estimates of total addressable market opportunity and growth forecasts are subject to significant uncertainty and may prove inaccurate.
• The dual-class stock structure may limit the ability of Class A common stockholders to influence corporate matters.
• The company does not intend to pay dividends on its Class A common stock, limiting shareholder returns to stock appreciation.
• The company is exposed to risks associated with international expansion, including unfamiliar foreign laws, regulatory requirements, and political instability.
• Headcount reductions undertaken to preserve capital may result in unintended consequences such as loss of institutional knowledge, decreased morale, and difficulty pursuing new opportunities.
• The company's information technology systems and data are vulnerable to security breaches, data losses, and cyber-attacks, which could compromise sensitive information and incur significant liabilities.
• The evolving regulatory landscape for artificial intelligence, particularly in healthcare, may impose additional burdens and costs on research, development, and compliance.
• Most favored nation provisions in contracts with third-party payers could limit revenue growth and lead to recoupment claims.
• Difficulty in collecting payments from patients when third-party payers deny coverage or only partially reimburse.

Risks

• Continued net losses and negative cash flows, requiring additional capital raises which may not be available on satisfactory terms or at all, potentially leading to curtailment or cessation of operations.
• Customer concentration risk due to reliance on a limited number of direct customers, including Elevance Health, for a significant portion of revenue.
• Inability to establish and maintain effective sales and marketing capabilities to drive adoption and commercialization of the PreTRM test and future products.
• Intense competition in the molecular diagnostics and proteomics industry from companies with greater resources and established market presence.
• Risk of product non-performance, errors, or inaccuracies in tests, leading to reputational damage, legal claims, or product discontinuation.
• Inoperability of the CLIA-certified laboratory facility due to natural disasters, contamination, or other events, which would halt testing operations.
• Substantial damages from product liability or professional liability claims exceeding insurance coverage.
• Clinical trial results may not consistently support test use, be replicated in later studies, or be compelling enough for the medical community or payers.
• Interim, top-line, and preliminary clinical trial data may change upon comprehensive review, leading to different conclusions.
• Compromise or destruction of the proprietary biobank through contamination, theft, cybersecurity breach, or natural disaster, impairing data reliance.
• Loss of access to internal or external databases critical for product and service functionality.
• Business, regulatory, political, operational, financial, and economic risks associated with international expansion, including data privacy laws and trade policies.
• Disruptions in third-party specimen collection (phlebotomy) and commercial courier delivery services.
• Reliance on a limited or single number of suppliers for laboratory instruments and materials, posing risks of supply shortages or increased costs.
• Limitations on the ability to utilize net operating loss carryforwards and other tax attributes due to ownership changes (Section 382 of the Internal Revenue Code).
• Inaccuracy of total addressable market opportunity estimates and market growth forecasts.
• Adverse impacts from an inflationary environment and unstable global economic and geopolitical conditions, including increased costs and potential changes in fiscal/monetary policy.
• Inadequate funding for government agencies (SEC, FDA, CMS) leading to delays in regulatory processes or business functions.
• Inadequate reimbursement for the PreTRM test or future products by third-party payers, including negative coverage determinations, insufficient rates, and prior authorization requirements.
• Billing disputes with third-party payers, potential recoupment requests for past payments, and challenges to billing practices.
• Withdrawal of coverage or lower reimbursement levels by third-party payers due to changing policies or billing complexities.
• Status as an out-of-network provider with large commercial insurers, potentially causing healthcare providers to avoid recommending tests.
• Changes in government healthcare policy (e.g., ACA, OBBBA, PAMA) increasing costs and negatively impacting coverage and reimbursement.
• Challenges to the validity of informed consent from patients, potentially precluding billing, forcing cessation of tests, or impacting clinical trial results.
• Changes in FDA regulation of reagents, consumables, and testing equipment, or increased scrutiny of Laboratory Developed Tests (LDTs), leading to delays or increased expenses.
• Failure to comply with federal and/or state laboratory licensing requirements, risking loss of testing ability.
• Federal Trade Commission (FTC) and/or state agencies objecting to promotional methods for tests or nonmedical products.
• Risks associated with social media use, including misinformation, reporting obligations, and inappropriate disclosure of sensitive information.
• Security breaches, data losses, and other disruptions compromising sensitive information and exposing the company to liability.
• Risks and challenges associated with the development and use of artificial intelligence, including security risks, bias, and evolving regulatory environments.
• Claims challenging the inventorship of patents and other intellectual property, potentially leading to loss of rights or costly litigation.
• Inability to prevent disclosure of trade secrets and other proprietary information, diminishing the value of tests and technology.
• Volatility in the price of Class A common stock due to various factors, including operating results, competition, regulatory changes, and overall market performance.
• Sales of a substantial number of shares by existing stockholders causing stock price decline.
• Inability to maintain effective disclosure controls and procedures, affecting financial reporting accuracy and investor confidence.

Future Outlook

Sera Prognostics anticipates continued operating losses for the foreseeable future as it invests in commercialization of the PreTRM test and development of its pipeline products. The company expects research and development expenses to decrease in 2026 but increase in the long-term, while selling and marketing expenses are projected to increase in 2026. General and administrative expenses are expected to remain consistent. The company aims to secure additional payer contracts and generate significant market adoption to achieve material revenues. It plans to integrate clinical study data into a health economic model for prospective customers and explore international expansion, initially focusing on Europe. The timing for the next new commercially available product is estimated to be months or years, dependent on performance data and capital availability. The company believes its existing cash and cash equivalents will fund operations through 2028.

Management Comments

• Our vision is to become the global leader in high-value women's health diagnostics by taking a holistic approach to providing pivotal and actionable information to pregnant women, their physicians, and health care payers.
• We believe that our method of combining the disciplines of proteomics and bioinformatics with rigorous clinical testing, data, and economic analysis enables us to provide physicians and expectant mothers with personally insightful, clinically meaningful, and economically impactful information.
• We believe that PRIME publication in context of ACOG's updated statement may create an opportunity for clinical opinion leaders to evaluate and issue guidelines around new technologies that can help with the risk assessments called for by ACOG.
• We believe the health benefits of this model translate favorably to health economic savings, creating a powerful value proposition to insurance payers.
• We believe market adoption by both health care providers and payers should be aided by the publications of data from our AVERT PRETERM TRIAL, PRIME study, and forthcoming real-world evidence studies.
• We believe data expected to be published in coming months and years, together with our current body of evidence, will continue to demonstrate the clinical and economic utility of using our test.
• Our commercial philosophy at this stage is to focus our sales and marketing efforts on a few geographies where we anticipate synergistic commercial momentum such as Medicaid pilots, local key opinion leader support, early adopter institutions, PRIME Study site locations, and other opportunities which we believe could combine to drive clinical utilization of the PreTRM test in that region.
• We expect that it may take a few quarters for each new sales representative to begin seeing significant density of adoption of this novel diagnostic test within their territory and to provide a favorable return on our commercial investment in such territories.
• We believe that as our database and sets of predictions grow, verifying and validating the predictions can lead to more rapid and efficient development required to commercialize such predictions in the future.

Industry Context

StockSavvy.ai notes that Sera Prognostics operates in the rapidly evolving women's health diagnostics sector, leveraging advanced proteomics and bioinformatics. The company's focus on preterm birth, a major health and economic burden, positions it in a market with significant unmet needs. The positive clinical trial results for PreTRM, particularly the demonstrated reductions in NICU admissions and neonatal morbidity/mortality, are crucial for gaining market acceptance and reimbursement in a competitive landscape. The emphasis on health economic savings aligns with broader industry trends towards value-based care models, which is critical for securing payer adoption. The company's pipeline expansion into other pregnancy complications like preeclampsia and gestational diabetes indicates a strategy to diversify its offerings and capture a larger share of the maternal health market, similar to other diagnostic innovators seeking to provide comprehensive solutions.

Comparison to Industry Standards

• The PreTRM test's NNS (Number Needed to Screen) to save a NICU admission is 38.5, which is at least three times more effective than the current standard of care for short cervix (NNS of 150) that utilizes transvaginal ultrasound plus progesterone treatments. This highlights a significant advantage in clinical efficacy compared to established methods.
• The PRIME study's findings of a 20% reduction in NICU admissions and neonatal morbidity/mortality, and a 56% reduction in babies born before 32 weeks, demonstrate a strong clinical impact that surpasses many incremental improvements seen in diagnostic interventions for complex conditions.
• The company's adherence to National Academy of Medicine (NAM) guidelines for developing and validating multi-omics predictions sets a high standard for scientific rigor, which is critical for gaining trust and adoption in the diagnostic community, especially for novel biomarker tests.
• The collaboration with Elevance Health, a major insurer covering over 10% of U.S. pregnancies, for early payment and data generation, is a strategic move to overcome reimbursement hurdles, a common challenge for new diagnostic technologies, by directly demonstrating value to a large payer.

Management Changes

Corporate Governance

Legal Proceedings

• The company is not currently a party to any material litigation or other material legal proceedings.

Related Party Transactions

• The company has a commercial collaboration agreement with Elevance Health (and its subsidiary Carelon Research) for the PreTRM test, which includes minimum test purchases and payments.
• The company paid Carelon Research $0.6 million in 2025 and $2.9 million in 2024 for research projects, including their role as a contract research organization for the PRIME study.
• In 2024, the company received $11.2 million from Elevance Health related to minimum payments for the year ended December 31, 2023, under the commercial collaboration agreement.
• In the February 2025 Offering, entities affiliated with one of the company's principal stockholders purchased pre-funded warrants for up to 11,250,000 shares of Class A common stock.
• Another principal stockholder purchased 625,000 shares of Class A common stock in the February 2025 Offering.

Stakeholder Impact

• **Shareholders:** The recent capital raise and positive clinical trial data could lead to increased investor confidence and potential stock appreciation, but ongoing net losses and the need for future funding pose dilution risks. The dual-class stock structure and anti-takeover provisions may limit shareholder influence.
• **Employees:** New employment agreements for executive officers provide updated compensation and severance terms. The company's growth strategy and focus on talent acquisition aim to benefit employees through competitive rewards and development opportunities, but headcount reductions have occurred and could recur.
• **Customers (Pregnant Women & Physicians):** The PreTRM test, supported by strong clinical evidence from the PRIME and AVERT studies, offers improved risk prediction for preterm birth, enabling earlier interventions and potentially better maternal and neonatal outcomes. The pipeline of new diagnostic tests promises further benefits for pregnancy care.
• **Payers (Insurance Companies):** The demonstrated health economic savings from the PreTRM test-and-treat strategy create a value proposition for insurers, potentially leading to broader coverage and reimbursement. However, ongoing negotiations and evolving reimbursement policies present challenges.
• **Suppliers:** The company's reliance on a limited number of suppliers for critical components creates supply chain risks, which could impact the timely delivery and cost-effectiveness of its products.
• **Creditors:** The company's ability to manage its significant operating losses and secure additional financing will be crucial for its financial stability and ability to meet its obligations.

Next Steps

• Integrate data from studies into a health economic model for prospective customers to estimate potential economic value.
• Process and submit publication manuscripts of additional PRIME data, including exploratory analyses and economic benefits, in the coming months.
• Study the effectiveness and implementation of the PreTRM test in a real-world setting through real-world evidence implementation programs.
• Expand payments for the PreTRM test to a variety of market segments and payment models, including integrated systems, institutional physician networks, self-insured employers, and major health insurance payers.
• Apply the proprietary platform capabilities to broaden the pipeline and develop novel products for other pregnancy-related conditions (e.g., preeclampsia, gestational diabetes, fetal growth restriction, stillbirth, postpartum depression).
• Continually enhance the value and capabilities of the proprietary technology platform through ongoing expansion and integration of biobank and proteomics/bioinformatics databases.
• Evolve testing, specimen collection, and shipping technologies, including migration to immunoassays and whole-blood collection/ambient shipping.
• Complete economic analyses for AVERT and PRIME studies and publish additional exploratory analyses related to the PRIME study.
• Engage with professional societies (SMFM, ACOG) to advocate for the inclusion of PreTRM in clinical guidelines.
• Partner with employers to include products in benefit packages for maternal care.
• Evaluate strategic partnerships to maximize the value of product offerings, including international expansion with an initial focus on Europe.
• Build a women's health commercial infrastructure, expanding field and inside sales, marketing, clinical/medical, customer service, managed care, and revenue cycle personnel.
• Build long-term relationships with expectant mother customers via digital channels to offer more products and solutions.
• Prepare the PreTRM Global test as a commercial ELISA-based in vitro diagnostic test kit for CE marking in the European Union and align the quality system with ISO 13485.
• Pursue ISO certification and prepare the PreTRM Global test technical dossier for conformity assessment by a designated Notified Body.

Key Dates

Recommendation

Sera Prognostics demonstrates promising clinical efficacy for its PreTRM test, backed by robust study results, and has a strategic pipeline for other pregnancy complications. The recent capital raise provides a necessary cash runway. However, the company continues to incur significant net losses and faces substantial challenges in achieving broad market adoption and consistent reimbursement from third-party payers. While the long-term potential is notable, the current financial performance and commercialization hurdles suggest a 'hold' position until clearer signs of sustainable revenue growth and a path to profitability emerge.

Keywords

Preterm Birth, Proteomics, Biomarker Test, Women's Health, Diagnostics, Pregnancy Complications, NICU, Clinical Trials, SEC Filing, 10-K, Sera Prognostics, PreTRM, Bioinformatics, Healthcare Costs, Equity Offering, Medical Devices, LDTs, AI, Data Privacy